GeneSight & Pharmacogenomics

Pharmacogenomic Testing and ADHD Medication

By Dr. Stacey Forbes, DNP, APRN, PMHNP-BC · Updated October 12, 2026

For most ADHD medications, a pharmacogenomic test adds little. The exception is atomoxetine, a non-stimulant, which depends heavily on the CYP2D6 enzyme: genetic poor metabolizers have roughly ten times the usual exposure, and the FDA label tells prescribers to consider testing. Stimulants such as amphetamine and methylphenidate have far weaker gene-drug evidence, and CPIC has issued no guideline for either. Testing can still help if atomoxetine is on the table, or if you are also choosing antidepressants. This guide explains what the evidence supports and how GeneSight presents ADHD medications.

The short version

If you are weighing stimulant and non-stimulant options in general, ADHD medications for adults and ADHD treatment beyond stimulants cover the bigger picture. This page sticks to genetics.

Atomoxetine and CYP2D6: the clearest case

Atomoxetine is cleared mainly by CYP2D6. Its label explains that CYP2D6 poor metabolizers carry two non-functional copies of the gene and have no CYP2D6 activity, and that their atomoxetine exposure is about 10 times higher, with peak levels about 5 times higher, than in other metabolizer types.

That difference shows up in side effects. In the label’s pediatric studies, the average heart-rate rise was 9.4 beats per minute in poor metabolizers versus 5 in others; in adults it was 11 versus 7.5. CPIC’s 2019 guideline adds that dose-related effects such as dry mouth, sleep problems, reduced appetite, constipation and tremor are more common in poor metabolizers.

The label is unusually direct for a psychiatric drug: it tells prescribers to consider genetic testing to determine CYP2D6 status, and it recommends a slower pace of dose increases for poor metabolizers. CPIC rates the pair level A. Its guideline also describes checking a blood level if the response is inadequate after about two weeks, and notes that ultrarapid metabolizers are unlikely to reach adequate levels with standard dosing, although data for that group are very limited.

CPIC also offers context: atomoxetine is not a first-line ADHD treatment, and unlike stimulants it takes time to reach its full effect. So genetic testing matters most once atomoxetine is actually being considered, or if it caused strong side effects before.

Stimulants: why genetics adds less

Amphetamine’s label says it is metabolized “to some degree” by CYP2D6, and that the enzymes involved in its breakdown have not been clearly defined. The FDA table lists amphetamine for CYP2D6 poor metabolizers in Section 1, with the advice to consider a lower starting dose or an alternative. CPIC, however, rates the amphetamine–CYP2D6 pair B/C and has not written a guideline, and methylphenidate–CYP2D6 is rated C with no guideline.

In practice, stimulant doses are usually adjusted step by step according to how you respond and what side effects appear, which is a built-in form of personalization. That is a large part of why a gene result changes stimulant care much less than it does atomoxetine. If a stimulant that used to help seems to have stopped working, why ADHD medication stops working covers the usual non-genetic reasons first.

How GeneSight presents ADHD medications

GeneSight’s sample report has a combined page for stimulants and non-stimulants. In that sample:

• Amphetamine salts, dextroamphetamine and lisdexamfetamine sit under No Proven Genetic Markers, with the note that a medication there “may be an effective choice based on other clinical factors.”
• Methylphenidate and dexmethylphenidate are categorized, and in the sample they carry note 4: genotype “may impact drug mechanism of action.”
• Atomoxetine, guanfacine and viloxazine are categorized in the columns; clonidine is listed with no proven markers.
• The pharmacodynamic gene page includes ADRA2A, described as suggesting a moderately reduced response to certain ADHD medications, and the pharmacokinetic page includes CES1A1 alongside CYP2D6.

It helps to know where these sit in the wider evidence. ADRA2A has no gene-drug pair in the CPIC database, and methylphenidate is not in the FDA table. Treat a methylphenidate flag as a prompt for discussion, not a reason to rule the drug out. For the parts of the report that apply across all classes, see how to read your GeneSight report.

Interactions matter as much as genes here

ADHD medications are sometimes combined with antidepressants, and that is where enzyme effects become practical. The atomoxetine label gives the same slower-titration advice for people taking a strong CYP2D6 inhibitor, such as fluoxetine, paroxetine or bupropion, as for genetic poor metabolizers. The amphetamine label warns that CYP2D6 inhibitors may raise amphetamine exposure and the risk of serotonin syndrome, and advises starting lower and monitoring if they must be combined.

So a normal CYP2D6 result does not mean much if you also take one of those antidepressants. When other medications change your genetic result explains this effect, called phenoconversion, in more detail.

When testing makes sense in ADHD care

• Atomoxetine is being considered, or you had marked side effects on it before. Here a CYP2D6 result directly shapes the plan.
• You also need an antidepressant and have had several that failed or caused side effects. The test covers both classes on one report.
• You already have a result from a past test. Bring it; your CYP2D6 genotype does not change over a lifetime.

Testing is less likely to help if you are starting a first stimulant and have no other medication questions. A carefully monitored trial usually answers the question faster.

At Willow & Stone, ADHD care is built on a thorough evaluation, and pharmacogenomic testing is added only when it is clinically useful. Dr. Stacey Forbes reviews any result with you alongside your history and other medications, as described on our GeneSight testing page. Telehealth prescribing of controlled ADHD medications follows federal and state rules; ADHD medication by telehealth explains where those stand.

Common Questions

Sources & Further Reading

• DailyMed — Strattera (atomoxetine) prescribing information
• CPIC guideline for CYP2D6 and atomoxetine (Brown et al., 2019)
• FDA — Table of Pharmacogenetic Associations
• DailyMed — Adderall XR (mixed amphetamine salts) prescribing information
• CPIC — Gene-drug pairs and levels
• GeneSight — Psychotropic sample report (version 4.3)

This article is general education, not advice for your situation. Do not start, stop, or change a medication based on a genetic test result without talking to the clinician who prescribes it.